Your new experience awaits. Try the new design now and help us make it even better

REVIEW article

Front. Oncol.

Sec. Molecular and Cellular Oncology

Volume 15 - 2025 | doi: 10.3389/fonc.2025.1703503

This article is part of the Research TopicNational Cancer Research Month 2025: Advances in Detection, Treatment and Therapies in OncologyView all 17 articles

Improving Radiation Therapy Efficacy Considering DNA Repair, TP53 Mutations, Microscopic Heterogeneity and Low & High Dose Apoptosis

Provisionally accepted
  • Karolinska Institutet Institutionen for onkologi-patologi, Stockholm, Sweden

The final, formatted version of the article will be published soon.

All radiation types produce d -rays of ≈1 keV that can impart MGy doses to 10 nm size volumes of DNA. These events can produce severe Dual Double Strand Breaks (DDSB) at the periphery of nucleosomes in single events particularly in heterochromatic DNA. These DDSBs are the most common multiply damaged sites and their probabilities are generally determining the biological effectiveness and therapeutic responses. The recent understanding that most normal tissues with intact TP53 genes generally are low-dose hypersensitive (LDHS) and low-dose apoptotic (LDA), implies that the well-known universal clinical fractionation window at ≈ 2 Gy/Fr defines the optimal tolerance level of most organs at risk and not the optimal tumor dose per fraction at least when using IMRT. Interestingly, practically all cancer cells are linked to genomic instability in some DNA repair, cell cycle or growth control genes like TP53 that is affected in more than 50% of all tumors. Unfortunately, this often gives tumor cells a low dose radiation resistant phenotype (LDRR). The fractionation window is due to the low-dose and LET initiation of full DNA repair capability after ≈½ Gy or 18 DSB, and we should use this acquired repair advantage in normal tissues to its full extent up to ≈2.3 Gy where the high dose apoptosis (HDA) start to set in. Understanding Quantum Biological Cure implies that light ions should truly have the lowest possible LET in normal tissues to retain the classical fractionation window but have a high LET only in the gross tumor region, e.g. carbon ions benefit from the last ≈10 GyE of the treatment be delivered by low LET (electrons or photons) to minimize normal tissue damage, get a steepest possible dose response and maximize complication free cure. Interestingly, this necessitates the use of the lightest ions with a low LET in normal tissues allowing quantum biology optimized molecular radiation therapy with He-Li-B ions, with minimal therapeutic effect in normal tissues and highest possible tumor apoptosis, senescence and cell kill in the tumor!

Keywords: TP53 damage sensors and modification sites, multiply damaged sites, dual nucleosomal double-strand breaks, low-dose hyper-sensitivity, low-dose apoptosis, light ion radiation therapy, Therapy optimization, optimal daily - weekly fractionation

Received: 11 Sep 2025; Accepted: 21 Oct 2025.

Copyright: © 2025 Brahme. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Anders Brahme, andersbrah@gmail.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.